Considerations for safe use of statins: Liver enzyme abnormalities and muscle toxicity

American Family Physician

Volumn 83, Issue 6, 2011, Pages 711-716

  Clark Gillett, R ^a   Norrell, Angelica ^a  

^a The Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATAZANAVIR; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; MEVINOLIN; PLACEBO; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; VERAPAMIL;

ARTICLE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFECT; GRAPEFRUIT JUICE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FUNCTION; LOW DRUG DOSE; MUSCLE DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; MYOSITIS; NONALCOHOLIC FATTY LIVER; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYMOLOGY; LIVER; LIVER FUNCTION TEST; REVIEW; SKELETAL MUSCLE; TOXIC HEPATITIS;

DRUG-INDUCED LIVER INJURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER FUNCTION TESTS; MUSCLE, SKELETAL; MUSCULAR DISEASES; RISK FACTORS;

EID: 79955961513     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. McKenney J.M, Davidson M.H, Jacobson T.A, Guyton J.R; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C-94C
2. De Denus S, Spinler S.A, Miller K, Peterson A.M. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24(5):584-591
3. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329(2):62-65
4. Chalasani N, Aljadhey H, Kesterson J, Murray M.D, Hall S.D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287-1292.
5. Avins A.L, Manos M.M, Levin T.R, et al. Lovastatin is not hepatotoxic to patients with pre-existing liver disease [abstract]. Gastroenterology. 2006;130(4 suppl 2):A595.
6. Lewis J.H, Fusco M.J, Medoff J.R, Mortensen M.E, Zweig S. Safety and efficacy of pravastatin 80 mg in 320 hyper-cholesterolemic patients with compensated chronic liver disease [abstract]. Gastroenterology. 2006;130(4 suppl 2):A65.
7. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4(7):902-907.
8. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102(12):1654-1662.
9. Bradford R.H, Shear C.L, Chremos A.N, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667-673.
10. Cannon C.P, Braunwald E, McCabe C.H, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004;350(15):1495-1504.
11. Zocor. In: Physicianś Desk Reference. 64th ed. Mont-vale, N.J.: Physicians ́ Desk Reference, Inc.; 2010:2290.
12. Rallidis LS, Drakoulis C.K, Parasi A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174(1):193-196.
13. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44(2):466-471.
14. Ekstedt M, Franzén L.E, Mathiesen U.L, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a his-topathological follow-up study. J Hepatol. 2007;47(1): 135-141.
15. Hortander J.C, Kwo P.Y, Cummings O.W, Koukoulis G. Atorvastatin for the treatment of NASH [abstract]. Gas-troenterology. 2001;120(5 suppl 1):A544.
16. Pasternak R.C, Smith S.C Jr, Bairey-Merz C.N, Grundy S.M, Cleeman J.I, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567-572.
17. Law M, Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C.
18. Thompson P.D, Clarkson P, Karas R.H. Statin-associated myopathy. JAMA. 2003;289(13):1681-1690.
19. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-414.
20. FDA drug safety communication. Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety. Accessed July 22, 2010.
21. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63(3):332-341.
22. Mevacor [package insert]. Whitehouse Station, N.J.: Merck & Co.; 2009.
23. Lipitor. In: Physicianś Desk Reference. 64th ed. Mont-vale, N.J.: Physicians' Desk Reference, Inc.; 2010:2704.
24. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 suppl 1):III50-III57.
25. Kantola T, Kivistö K.T, Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64(2):177-182.
26. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf. 2005;28(8):677-694.
27. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62(3):311-321.
28. Crestor [package insert]. Wilmington, Del.: AstraZen-eca Pharmaceuticals; 2010.
29. Lescol [package insert]. East Hanover, N.J.: Novartis Pharmaceuticals Corp.; 2006.
30. Pitavastatin [package insert]. Cincinnati, Ohio: Kowa Pharmaceuticals America; 2009.
31. Reaven P, Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109(7):597-598.
32. Graham D.J, Staffa J.A, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590.
33. Lang J.E, Wang P, Glueck C.J. Myopathy associated with lipid lowering therapy in patients with previously undi-agnosed or undertreated hypothyroidism. Clin Chim Acta. 1996;254(1):65-92.
34. Song S.K, Rubin E. Ethanol produces muscle damage in human volunteers. Science. 1972;175(19):327-328.
35. Guyton J.R, Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 1998;82(12A):82U-84U.
36. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
37. Sathasivam S, Lecky B. Stain induced myopathy. BMJ. 2008;337:a2286.
38. Hansen K.E, Hildebrand J.P, Ferguson E.E, Stein J.H. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671-2676.